Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)

Journal of Thoracic Oncology

Volumn 3, Issue 10, 2008, Pages 1159-1165

  Miller, Antonius A ^a   Wang, Xiaofei F ^b   Gu, Lin ^b   Hoffman, Philip ^c   Khatri, Jamil ^d   Dunphy, Frank ^b   Edelman, Martin J ^e   Bolger, Michael ^f   Vokes, Everett E ^c   Green, Mark R ^g  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d CHRISTIANA CARE HEALTH SYSTEM   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f MISSOURI BAPTIST MEDICAL CENTER   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cisplatin; Docetaxel; Dose dense; Non small cell lung cancer; Phase II

Indexed keywords

CISPLATIN; CREATININE; DIMESNA; DOCETAXEL; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; 2,2' DITHIODIETHANESULFONIC ACID; 2,2'-DITHIODIETHANESULFONIC ACID; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN; MESNA; TAXOID; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INCIDENCE; KIDNEY FAILURE; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL TIME; THERAPY DELAY; THROMBOCYTE COUNT; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; ANEMIA; BRAIN TUMOR; DOSE RESPONSE; DRUG COMBINATION; LUNG ALVEOLUS CELL CARCINOMA; LUNG TUMOR; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; FEASIBILITY STUDIES; FEMALE; FILGRASTIM; HEMATINICS; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MESNA; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PROGNOSIS; SURVIVAL RATE; TAXOIDS;

EID: 58949087471     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318186fb0d     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC lung cancer staging project: Validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol 2007;2:694-705.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
4. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-857.
5. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorel-bine plus cisplatin for advanced non-small cell lung cancer: The TAX 326 study group. J Clin Oncol 2003;21:3016-3024.
6. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003;21:1431-1439.
7. Koukourakis MI, Giatromanoloaki A, Kakolyris S, et al. Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer. Med Oncol 2000;17:135-143.
8. Miller VA, Krug LM, Ng KK, et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. J Clin Oncol 2000;18:1346-1350.
9. Galetta D, Gebbia V, Giotta F, et al. Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2002;38:79-84.
10. Hausheer FH, Kanter P, Cao S, et al. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first-and second-generation protecting agents. Semin Oncol 1998;25:584-599.
11. Boven E, Verschraagen M, Hulscher TM, et al. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer 2002;38:1148-1156.
12. Pendyala L, Schwartz G, Smith P, et al. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer Chemother Pharmacol 2003;51:376-384.
13. Verschraagen M, Boven E, Ruijter R, et al. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites. Clin Pharmacol Ther 2003;74:157-169.
14. Schilsky RL, Desai A, Creaven P, et al. BNP7787 (B) permits safe administration of paclitaxel (P) and cisplatin(C) without IV hydration. Proc Am Soc Clin Oncol 2003;22:148.
15. Hausheer FH, Schilsky RL, Bain S, et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006;33:15-49.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
18. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
19. Lilenbaum RC, Herndon JE, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 2005;23: 190-196.
20. Langer CJ, Manola J, Bernado P, et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-181.
21. Lee JJ, Swaim SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 2006;24:1633-1642.
22. Wieand HS. Randomized phase II trials: what does randomization gain? J Clin Oncol 2005;23:1794-1795.
23. Socinski MA, Stinchcombe TE. Duration of first-line chemotherapy in advanced non-small-cell lung cancer: less is more in the era of effective subsequent therapies. J Clin Oncol 2007;25:5155-5157.